A clinical briefing on Cefixime availability in 2026. Supply status, prescribing implications, cost considerations, alternatives, and tools for providers.
Cefixime (Suprax), a third-generation oral cephalosporin with a well-established role in outpatient infectious disease management, has become increasingly difficult for patients to locate at retail pharmacies. While not currently listed on the FDA or ASHP drug shortage databases, practical access barriers — limited manufacturers, inconsistent pharmacy stocking, and supply chain fragility — are causing patient-level dispensing delays.
This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and tools available to help your patients fill their prescriptions.
Cefixime was FDA-approved in 1989 and has been available generically since its patent expiration. The drug's U.S. market history includes a notable disruption: brand-name Suprax was withdrawn from the market in 2002 by Wyeth and subsequently reintroduced in 2004 by Lupin Pharmaceuticals.
Currently, generic Cefixime is manufactured primarily by Lupin Pharmaceuticals and Aurobindo Pharma. This limited manufacturer base creates vulnerability — a production delay or quality hold at either facility can significantly impact national supply. The broader context of global antibiotic API sourcing adds additional risk, as most active ingredients are manufactured overseas.
As of Q1 2026, Cefixime is not on the FDA Drug Shortages list or the ASHP Current Shortages list. However, anecdotal and patient-reported data suggest inconsistent availability at the pharmacy level, particularly at large chain pharmacies.
Cefixime's FDA-approved indications include:
Cefixime has historically been an important oral option for gonorrhea treatment. However, the CDC's current STI treatment guidelines recommend Ceftriaxone 500 mg IM as first-line therapy for uncomplicated gonorrhea, with Cefixime 800 mg oral as an alternative when Ceftriaxone is not available. Providers should be aware that if prescribing Cefixime for gonorrhea, ensuring the patient can actually fill the prescription is critical for public health outcomes.
Cefixime remains a valuable option in pediatric populations (≥6 months) for otitis media and pharyngitis, particularly at 8 mg/kg/day dosing. The oral suspension (100 mg/5 mL, 200 mg/5 mL, 500 mg/5 mL) and chewable tablets (100 mg, 150 mg, 200 mg) provide dosing flexibility. However, verify pharmacy availability before prescribing, as liquid formulations may be less commonly stocked than capsules.
Key interactions to document and monitor:
For complete interaction information, see Cefixime Drug Interactions: What to Avoid.
The availability landscape for Cefixime in 2026 can be characterized as follows:
Providers can direct patients to Medfinder for Providers to check real-time pharmacy stock before patients leave the clinic.
Cost can be a barrier or facilitator for access:
No manufacturer copay cards or savings programs are currently available for generic Cefixime or brand Suprax. Patient assistance through organizations like Prescription Hope ($70/month for Suprax) and NeedyMeds may help qualifying patients.
Recommending patients use discount cards at the point of prescribing can meaningfully improve fill rates. Consider noting "discount card acceptable" on prescriptions or discussing cost proactively with patients.
Medfinder for Providers allows your staff to verify pharmacy stock before sending a prescription, reducing callbacks and patient frustration. Integrating this check into your prescribing workflow can prevent the cycle of unfilled prescriptions and patient no-shows.
When Cefixime is unavailable, consider these evidence-based alternatives based on indication:
| Indication | Alternatives |
|---|---|
| UTI (uncomplicated) | Cefpodoxime 100 mg BID × 7d; Nitrofurantoin 100 mg BID × 5d; TMP-SMX DS BID × 3d |
| Otitis media | Cefdinir 300 mg BID × 10d; Cefpodoxime 200 mg BID × 10d; Amoxicillin-Clavulanate |
| Pharyngitis/tonsillitis | Cefdinir 300 mg BID × 10d; Cephalexin 500 mg BID × 10d; Penicillin V 500 mg BID × 10d |
| Gonorrhea | Ceftriaxone 500 mg IM (preferred); Gentamicin 240 mg IM + Azithromycin 2g PO (if cephalosporin-allergic) |
| Acute bronchitis exacerbation | Cefdinir 300 mg BID; Cefpodoxime 200 mg BID; Azithromycin 500 mg day 1, 250 mg days 2–5 |
For a patient-facing version, see Alternatives to Cefixime.
The broader trend of antibiotic supply chain consolidation continues to pose risks for medications like Cefixime that have limited manufacturers and relatively low prescribing volume. Key developments to watch:
Cefixime remains a clinically valuable oral cephalosporin, but its practical availability requires proactive management. The most effective approach for providers is to:
For a complementary provider resource on helping patients navigate Cefixime access, see How to Help Your Patients Find Cefixime in Stock: A Provider's Guide. For cost-saving guidance to share with patients, see How to Help Patients Save Money on Cefixime.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
